封面
市場調查報告書
商品編碼
1132593

美國真實世界證據(RWE)解決方案市場:按組件(數據集(臨床,計費,藥房,集成),服務),應用程序(市場准入,腫瘤學,神經病學),用戶(製藥,醫療保健交付人)預測~2029

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy, Integrated), Services], Application (Market Access, Oncology, Neurology), End User (Pharma Companies, Providers) - Forecast to 2029

出版日期: | 出版商: Meticulous Research | 英文 103 Pages | 訂單完成後即時交付

價格

美國真實世界證據 (RWE) 解決方案的市場規模預計在 2022 年至 2029 年間以 13.1% 的複合年增長率增長,到 2029 年達到 22.2 億美元。推動市場增長的關鍵因素包括慢性病和傳染病發病率的增加、藥物開發的延遲和相關的開發成本增加、對個性化醫療、基於體積價值的醫療的日益關注以及大數據的迅速崛起在醫療保健。

本報告研究了美國真實世界證據 (RWE) 解決方案市場,其中包括市場概況、市場規模和預測、趨勢、驅動因素和限制、競爭格局、組件、應用程序和終端它提供用戶特定的分析,公司簡介等。

內容

第一章介紹

  • 市場定義
  • 市場生態系統
  • 貨幣

第二章研究方法

  • 研究過程
  • 數據收集和驗證
    • 二次調查
    • 初步調查
  • 市場評估
    • 市場規模預測
    • 市場份額分析
  • 調查先決條件
  • 調查限制

第 3 章執行摘要

第 4 章市場洞察

  • 市場概覽
  • 驅動程序
    • 慢性病和傳染病負擔上升
    • 對個性化醫療的興趣日益濃厚
    • 藥物開發延遲並隨之增加開發成本
    • 轉向基於價值的護理
    • 大數據在醫療保健領域的快速擴張
  • 限制因素
    • 不願依賴真實世界的研究
  • 機會
    • 對端到端 RWE 服務的興趣日益濃厚
    • RWE 越來越多地採用可穿戴設備和人工智能
  • 任務
    • 缺乏開發 RWE 的標準化方法
  • 主要市場趨勢
    • 在藥物開發和商業化中擴大 RWE 的採用
    • 合併數量增加
    • 基於 RWE 改善患者治療效果並創造價值
  • 評估 COVID-19 對美國真實世界證據 (RWE) 解決方案市場的影響

第 5 章監管分析:美國真實世界證據 (RWE) 解決方案市場

第 6 章定價模型(EMR/基因組學/集成數據集)

  • 簡介
  • 按患者記錄付費(基於數量的定價)
  • 即用即付系統(基於價值的定價)
  • 年費

第 7 章。美國真實世界證據 (RWE) 解決方案市場:按組件

  • 簡介
  • 數據集
    • 異構數據集
    • 綜合數據集
  • 諮詢和分析

第 8 章。美國真實世界證據 (RWE) 解決方案市場:按應用分類

  • 簡介
  • 確定市場准入和贖回/覆蓋範圍
  • 藥物開發和批准
    • 腫瘤學
    • 神經科
    • 免疫學
    • 心血管疾病
    • 其他治療領域
  • 醫療器械的開發和審批
  • 上市後監督
  • 其他

第 9 章。美國真實世界證據 (RWE) 解決方案市場:按最終用戶分類

  • 簡介
  • 製藥、生物技術和醫療器械公司
  • 醫療費用支付方
  • 醫療保健提供者
  • 其他

第 10 章競爭格局

  • 簡介
  • 主要增長戰略
  • 競爭基準
  • 市場份額分析(2020 年)
    • IQVIA Holdings, Inc.
    • 圖標公司
    • PPD, Inc.

第 11 章公司簡介(業務概覽、財務概覽、解決方案組合、戰略發展)

  • Anthem, Inc.
  • Clinigen Group plc.
  • Cognizant Technology Solutions Corporation
  • ICON plc
  • IQVIA HOLDINGS INC.
  • Oracle Corporation
  • PAREXEL International Corporation
  • PerkinElmer, Inc.
  • PPD, Inc.
  • SAS Institute Inc.
  • UnitedHealth Group Incorporated
  • Flatiron Health, Inc.
Product Code: MRHC - 104556

U.S. Real-World Evidence (RWE) Solutions Market by Component [Datasets (Clinical, Claims, Pharmacy), Services], Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers)- Forecast to 2029

The U.S. RWE solutions market is expected to grow at a CAGR of 13.1% from 2022 to 2029 to reach $2.22 billion by 2029

Following a thorough secondary and primary research and in-depth analysis of the market scenario, the report carries out the key industry drivers, restraints, challenges, and opportunities

Growing incidence of chronic & infectious diseases, delays in drug development and the subsequent increase in development costs, rising focus towards personalized healthcare, a shift from volume to value-based care, and rapidly growing big data in healthcare are the key factors driving steady growth in the U.S. RWE solutions market. Further, significant opportunities for existing market players and new entrants are provided by rising focus on end-to-end RWE services, and rising adoption of wearable devices and AI in RWE

Based on component, in 2022, the datasets segment is expected to command the largest share in the market. Real-world data (RWD) are derived from various sources associated with outcomes in a heterogeneous patient population in real-world settings. Datasets are present in a secondary format on which retrospective studies are conducted to generate real-world evidence. This real-world evidence provides meaningful insights into unmet needs and the clinical and economic impacts on patients and healthcare systems. It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials.

Based on application, the drug development & approvals segment is expected to show the fastest growth rate in the forecast period. Factors attributing towards the growth of this segment are increasing demand for real-world data and real-world evidence to accelerate drug discovery and development, and increasing investments by biopharmaceutical companies in R&D.

In the field of drug development, quality-of-life metrics, and Patient-Reported Outcome Measures (PROMs) are now becoming common elements in clinical trials. The evidence generated from real-world data is regularly utilized to inform aspects of drug development. The role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs.

Based on end user, the pharmaceutical & medical device companies segment is expected to show the fastest growth rate in the forecast period. The growth of this segment is primarily attributed to the increasing importance of RWE studies in drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

The cost of developing a new drug was more than ~USD 2,600 million in 2020 compared to USD 802 million in 2003. This increase in drug development costs reflects various technical, regulatory, and economic challenges pharmaceutical R&D pipelines face.

The key companies operating in the U.S. RWE solutions market are Anthem, Inc. (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), ICON plc (Ireland), IQVIA HOLDINGS INC. (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), PPD, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health, Inc. (U.S.).

Scope of the Report

U.S. RWE Solutions Market, by Component

  • Datasets
  • Disparate Datasets
  • EMR/EHR/Clinical Data
  • Claims & Billing Data
  • Pharmacy Data
  • Product/Disease Registries Data
  • Other Disparate Datasets
  • Integrated Datasets
  • Consulting and Analytics

(Note - Other Disparate Datasets include data generated from mobile devices, wearable devices, and social media)

U.S. RWE Solutions Market, by Application

  • Market Access & Reimbursement/Coverage Decisions
  • Drug Development & Approvals
  • Oncology
  • Neurology
  • Immunology
  • Cardiovascular Diseases
  • Other Therapeutic Areas
  • Post Market Surveillance
  • Medical Device Development & Approvals
  • Clinical and Regulatory Decision-Making

(Note - Other Therapeutic Areas include infectious diseases, musculoskeletal disorders, dermatological diseases, and respiratory diseases)

U.S. RWE Solutions Market, by End User

  • Pharmaceutical, Biotechnology, and Medical Device Companies
  • Healthcare Payers
  • Healthcare Providers
  • Other End Users

(Note - Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies)

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition
  • 1.2. Market Ecosystem
  • 1.3. Currency

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
      • 2.3.1.1. Bottom-Up Approach
      • 2.3.1.2. Top-Down Approach
      • 2.3.1.3. Growth Forecast
    • 2.3.2. Market Share Analysis
  • 2.4. Assumptions for the Study
  • 2.5. Limitations for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Market Overview
  • 4.2. Drivers
    • 4.2.1. Growing Burden of Chronic and Infectious Diseases
    • 4.2.2. Rising Focus Towards Personalized Healthcare
    • 4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
    • 4.2.4. Shift Towards Value-Based Care
    • 4.2.5. Rapidly Growing Big Data in Healthcare
  • 4.3. Restraints
    • 4.3.1. Reluctance to Rely on Real-World Studies
  • 4.4. Opportunities
    • 4.4.1. Rising Focus on End-to-End RWE Services
    • 4.4.2. Rising Adoption of Wearable Devices and Artificial Intelligence in RWE
  • 4.5. Challenges
    • 4.5.1. Lack of Standardized Methodologies to Develop RWE
  • 4.6. Key Market Trends
    • 4.6.1. Growing Adoption of RWE in Drug Development and Commercialization
    • 4.6.2. Rising Number of Consolidations
    • 4.6.3. Improved Patient Outcomes and Value Creation from Real-World Evidence
  • 4.7. Impact Assessment of COVID-19 on the U.S. RWE Solutions Market

5. Regulatory Analysis - U.S. Real-World Evidence (RWE) Solutions Market

6. Pricing Models (EMR/Genomic/Integrated Datasets)

  • 6.1. Introduction
  • 6.2. Pay Per Patient Record (Volume-Based Pricing)
  • 6.3. Pay Per Usage (Value-Based Pricing)
  • 6.4. Annual Subscription

7. U.S. Real-World Evidence Solutions Market, by Component

  • 7.1. Introduction
  • 7.2. Datasets
    • 7.2.1. Disparate Datasets
      • 7.2.1.1. EMR/EHR/Clinical Data
      • 7.2.1.2. Claims & Billing Data
      • 7.2.1.3. Pharmacy Data
      • 7.2.1.4. Product/Disease Registries Data
      • 7.2.1.5. Other Disparate Datasets
    • 7.2.2. Integrated Datasets
  • 7.3. Consulting & Analytics

8. U.S. Real-World Evidence Solutions Market, by Application

  • 8.1. Introduction
  • 8.2. Market Access & Reimbursement/Coverage Decisions
  • 8.3. Drug Development & Approvals
    • 8.3.1. Oncology
    • 8.3.2. Neurology
    • 8.3.3. Immunology
    • 8.3.4. Cardiovascular Diseases
    • 8.3.5. Other Therapeutic Areas
  • 8.4. Medical Device Development & Approvals
  • 8.5. Post-Market Surveillance
  • 8.6. Other Applications

9. U.S. Real-World Evidence Solutions Market, by End User

  • 9.1. Introduction
  • 9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 9.3. Healthcare Payers
  • 9.4. Healthcare Providers
  • 9.5. Other End Users

10. Competitive Landscape

  • 10.1. Introduction
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Market Share Analysis (2020)
    • 10.4.1. IQVIA Holdings, Inc. (U.S.)
    • 10.4.2. ICON plc (Ireland)
    • 10.4.3. PPD, Inc. (U.S.)

11. Company Profiles (Business Overview, Financial Overview, Solution Portfolio, Strategic Developments)

  • 11.1. Anthem, Inc.
  • 11.2. Clinigen Group plc.
  • 11.3. Cognizant Technology Solutions Corporation
  • 11.4. ICON plc
  • 11.5. IQVIA HOLDINGS INC.
  • 11.6. Oracle Corporation
  • 11.7. PAREXEL International Corporation
  • 11.8. PerkinElmer, Inc.
  • 11.9. PPD, Inc.
  • 11.10. SAS Institute Inc.
  • 11.11. UnitedHealth Group Incorporated
  • 11.12. Flatiron Health, Inc.

List of Tables

  • Table 1 U.S. Real-World Evidence Solutions Market Drivers: Impact Analysis (2022-2029)
  • Table 2 Total Per-Study Cost (In Usd Million), by Phase and Therapeutic Area
  • Table 3 Sources of Healthcare Data
  • Table 4 U.S. Real-World Evidence Solutions Market Restraints: Impact Analysis (2022-2029)
  • Table 5 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)
  • Table 6 U.S. Real-World Evidence Solutions Market Size, by Component, 2012-2029 (USD Million)
  • Table 7 U.S. Real-World Evidence Datasets Market Size, by Type, 2020-2029 (USD Million)
  • Table 8 U.S. RWE Disparate Datasets Market Size, by Type, 2020-2029 (USD Million)
  • Table 9 U.S. Real-World Evidence Solutions Market Size, by Application, 2020-2029 (USD Million)
  • Table 10 U.S. RWE Solutions Market Size for Drug Development & Approvals, by Therapeutic Area, 2020-2029 (USD Million)
  • Table 11 Estimated Number of New Cancer Cases in the U.S. (2019-2023)
  • Table 12 Medical Costs Associated With Cardiovascular Diseases (2010-2030) (USD Billion)
  • Table 13 Other Therapeutic Areas: Drugs in the R&D Pipeline
  • Table 14 U.S. RWE Solutions Market Size, by End User, 2020-2029 (USD Million)
  • Table 15 Recent Developments, by Company, 2018-2022

List of Figures

  • Figure 1 Key Stakeholders
  • Figure 2 Research Process
  • Figure 3 Key Secondary Sources
  • Figure 4 Primary Research Techniques
  • Figure 5 Key Executives Interviewed
  • Figure 6 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 7 Market Size Estimation
  • Figure 8 U.S. Real-World Evidence Solutions Market, by Component, 2022 Vs. 2029 (USD Million)
  • Figure 9 U.S. Real-World Evidence Solutions Market, by Application, 2022 Vs. 2029 (USD Million)
  • Figure 10 U.S. Real-World Evidence Solutions Market, by End User, 2022 Vs. 2029 (USD Million)
  • Figure 11 Market Dynamics
  • Figure 12 Number of People in the U.S. With Chronic Conditions (2000-2030)
  • Figure 13 Percentage of Personalized Medicines Approved (2015-2020)
  • Figure 14 U.S. Real-World Evidence Solutions Market Size, by Component, 2022-2029 (USD Million)
  • Figure 15 U.S.: Number of E-Prescriptions, 2013-2020 (Billions)
  • Figure 16 U.S. Real-World Evidence Solutions Market Size, by Application, 2022-2029 (USD Million)
  • Figure 17 Dalys of Neurological Disorders in the U.S., 2010-2021 (In Thousands)
  • Figure 18 U.S.: Hepatitis A Virus (HAV) Infections, 2013-2020
  • Figure 19 U.S. Real-World Evidence Solutions Market Size, by End User, 2022-2029 (USD Million)
  • Figure 20 U.S. Pharmaceutical R&D Spending, 1980-2019 (USD Billion)
  • Figure 21 Key Growth Strategies Adopted by Leading Players (2018-2022)
  • Figure 22 U.S. Real-World Evidence Solutions: Competitive Benchmarking
  • Figure 23 Market Share Analysis: U.S. Real-World Evidence Solutions Industry (2021)
  • Figure 24 Anthem, Inc.: Financial Overview (2021)
  • Figure 25 Clinigen Group plc: Financial Overview (2021)
  • Figure 26 Cognizant Technology Solutions Corporation: Financial Overview (2021)
  • Figure 27 ICON plc: Financial Overview (2021)
  • Figure 28 IQVIA HOLDINGS INC.: Financial Overview (2021)
  • Figure 29 Oracle Corporation: Financial Overview (2021)
  • Figure 30 PerkinElmer, Inc.: Financial Overview (2022)
  • Figure 31 PPD, Inc.: Financial Overview (2020)
  • Figure 32 SAS Institute Inc.: Financial Overview (2021)
  • Figure 33 UnitedHealth Group Incorporated.: Financial Overview (2021)